Investigation Notice for uniQure N.V. by Kessler Topaz Meltzer & Check, LLP

uniQure N.V., a biotechnology company traded on the NASDAQ under the ticker symbol QURE, is currently the subject of an investigation by Kessler Topaz Meltzer & Check, LLP, a renowned law firm in Radnor, Pennsylvania. The investigation was prompted by a recent press release from uniQure on November 3, 2025. In their statement, uniQure disclosed that the FDA had notified them that the data provided for their investigational gene therapy, AMT-130, intended to treat Huntington’s disease, did not meet the necessary requirements to support a Biologics License Application (BLA) submission.

The implications of the FDA’s feedback were profound for uniQure. The company now faces uncertainties about the timing of its BLA submission for AMT-130, as the FDA no longer considers the data from the Phase I/II studies of AMT-130 to be sufficient primary evidence for the submission. This unforeseen development had a significant impact on uniQure’s stock price, causing it to plummet by over 50% in just a matter of days. Starting from a closing price of $67.69 on October 31, 2025, the stock fell to $34.29 by November 3, 2025, reflecting investor apprehension about the company’s future prospects in light of the FDA’s feedback.

Investors who have suffered substantial losses as a result of uniQure’s stock decline are encouraged to contact Kessler Topaz Meltzer & Check, LLP to participate in the ongoing investigation. The law firm is actively reviewing potential violations of federal securities laws that may have occurred due to the recent events surrounding uniQure. By reaching out to Kessler Topaz Meltzer & Check, LLP, investors can gain more insights into the investigation and understand their legal options moving forward.

Kessler Topaz Meltzer & Check, LLP is a prominent plaintiff-side law firm specializing in securities-fraud class actions and global investor protection. The firm is dedicated to representing both individual and institutional investors, including pension funds, asset managers, and international investors. With a track record of spearheading large-scale recoveries in securities litigation, Kessler Topaz Meltzer & Check, LLP has earned recognition from legal experts and peers for its exceptional legal work.

Operating on a global scale with offices in Pennsylvania and California, Kessler Topaz Meltzer & Check, LLP is committed to upholding the rights of investors and ensuring accountability in the financial markets. For more information about the law firm and its services, visit their official website to learn more about how they can assist investors in navigating complex legal matters arising from investments.

In conclusion, the investigation into uniQure N.V. by Kessler Topaz Meltzer & Check, LLP underscores the importance of safeguarding investors’ interests and holding companies accountable for complying with regulatory standards. The developments surrounding uniQure’s AMT-130 gene therapy highlight the risks inherent in the biotechnology sector and serve as a reminder of the potential volatility in the stock market. Investors affected by uniQure’s recent stock decline are encouraged to seek legal advice and explore their options with experienced legal professionals like Kessler Topaz Meltzer & Check, LLP.